These two get shelved together as "immune mushrooms" and their evidence could hardly be further apart. Trametes Versicolor's polysaccharide fraction has randomised survival data published in The Lancet. Chaga has no completed human randomised trial of any kind, and two published case reports of kidney failure. That's not a close comparison — but the honest version has a catch that cuts against Trametes too, and almost nobody mentions it.
Trametes Versicolor's evidence comes from PSK (polysaccharide-K, marketed as Krestin), a standardised pharmaceutical preparation used as an adjuvant in Japan. In a 262-patient randomised trial across 46 institutions with at least five years of follow-up, adding PSK to standard chemotherapy after gastric surgery raised the five-year disease-free rate to 70.7% from 59.4% (p = 0.047) and five-year survival to 73.0% from 60.0% (p = 0.044). A separate double-blind trial in 111 colorectal patients found significantly longer disease-free periods on PSK. Chaga has no equivalent. What it does have is two published case reports of oxalate nephropathy, one ending in end-stage renal disease in a 49-year-old man whose chaga powder was measured at 14.2 g of oxalate per 100 g. The catch: PSK is a prescription-grade product, not the dried mushroom sold as a supplement.
So which one should you actually buy? That depends on whether you want the species with the research or the species with the research you can actually purchase — and those aren't the same answer.
What Does Trametes Versicolor Have Behind It?
Two randomised controlled trials with hard endpoints, which is more than almost anything else in this category can claim.
Nakazato's 1994 study in The Lancet randomised 262 patients who'd undergone curative gastrectomy across 46 Japanese institutions to standard adjuvant chemotherapy alone or with PSK added. Minimum follow-up was five years. The PSK arm reached a 70.7% five-year disease-free rate against 59.4%, and 73.0% five-year survival against 60.0%. Toxic effects were slight and didn't differ significantly between groups.
Torisu's 1990 double-blind trial gave PSK to 56 colorectal patients after curative surgery and placebo to 55. Both disease-free period and survival came out significantly higher on PSK, and the authors traced a mechanism: polymorphonuclear leukocytes from treated patients showed enhanced locomotion and phagocytic activity.
These are hospital studies of an adjuvant used alongside chemotherapy in people who'd had cancer surgery. They are not evidence that a mushroom tea does anything for a healthy person's immune system, and it matters that nobody has tested that question.
What Does Chaga Have Behind It?
Laboratory work, animal studies, and a great deal of marketing. A PubMed search for completed randomised human trials of Inonotus obliquus returns nothing usable.
That's not the same as saying chaga does nothing. Its betulin and betulinic acid content is real, its melanin content is unusual, and the antioxidant chemistry is genuinely interesting. But every claim you'll read about chaga and immunity traces back to cell culture or rodents, and our chaga immune article is explicit about where that chain stops.
An absence of trials is not proof of absence of effect. It's just an absence of trials, and after decades of commercial interest that absence has started to look like an answer of its own.
Is the PSK Evidence Transferable to a Supplement?
No, and this is the part the Trametes marketing quietly skips.
PSK is a protein-bound polysaccharide extracted and standardised to pharmaceutical specification, approved in Japan and prescribed there. The trials above used that material, at pharmaceutical doses, in patients receiving chemotherapy under hospital supervision.
A bag of dried Trametes Versicolor is a different product. Its polysaccharide content varies with the log it grew on, the extraction it received and the batch it came from, and no trial has ever tested it. The gap between "this species has Lancet data" and "this jar does something" is enormous, and it's exactly the gap we describe in our Trametes versus reishi comparison.
So both species have an evidence-transfer problem. Chaga's is that there's no evidence to transfer. Trametes's is that the evidence belongs to a product you can't buy.
Which One Is Safer?
Trametes, clearly, and this ends up being the decisive column.
Chaga is unusually high in oxalate. Lee's 2020 case report describes a 49-year-old Korean man who developed end-stage renal disease after taking chaga powder long-term for intractable atopic dermatitis. The team measured the oxalate content of his remaining powder: 14.2 g per 100 g. His estimated daily oxalate intake ran at twice the normal dietary figure for four years and five times for one. Kidney biopsy showed chronic tubulointerstitial nephritis with oxalate crystal deposits.
Kwon's 2022 report adds a second case, an oxalate nephropathy that presented clinically as nephrotic syndrome. Two cases is not an epidemic, and both involved heavy long-term use — but they're two more serious adverse outcomes than Trametes Versicolor has accumulated in decades of clinical use. We cover the dose and vitamin C interaction in our oxalates and kidney health article.
How Do They Compare Head to Head?
| Trametes Versicolor | Chaga | |
|---|---|---|
| Randomised human trials | Yes — at least two with survival endpoints | None completed |
| What was actually tested | PSK, a prescription-grade standardised extract | — |
| Population studied | Post-surgical patients on chemotherapy | — |
| Mechanism evidence in humans | Enhanced leukocyte locomotion and phagocytosis | In vitro and animal only |
| Documented serious harm | None notable | Two oxalate nephropathy cases, one ESRD |
| Key compounds | PSK, PSP (protein-bound polysaccharides) | Betulin, betulinic acid, inotodiol, melanin |
| Best consumer format | Hot-water extract or long simmer | Chunks simmered; avoid heavy daily powder |
| Who should avoid it | Autoimmune conditions, immunosuppressants | Anyone with kidney risk or a stone history |
Do They Do the Same Thing at All?
Not really, once you look past the shared "immune" label.
Trametes's demonstrated human effect is immunological in a specific, measurable way — leukocyte activity in patients whose immune systems had been suppressed by surgery and chemotherapy. That's immune modulation with a named mechanism and a measured outcome.
Chaga's story is antioxidant and anti-inflammatory, built on polyphenol and triterpene chemistry. Whether it's an immune product at all is a marketing decision rather than a scientific one. Selling them as competitors in the same category obscures that they're making different claims with very different support.
Can You Take Both Together?
There's no interaction study, and nothing suggests a direct conflict. The practical answer depends on your kidneys rather than on any interaction.
If you've had kidney stones, have reduced kidney function, take high-dose vitamin C, or are on a medication list that already stresses the kidneys, chaga is the one to drop — not because it's combined with Trametes, but because it carries a documented risk on its own. Otherwise, both at ordinary intakes is unremarkable. Our stacking guide covers sensible combinations.
Which Should You Buy?
- If you want the species with human trials, that's Trametes Versicolor. Just don't expect your bag to equal PSK — the trials tested a prescription-grade preparation.
- Buy Trametes as a hot-water preparation. PSK is a water-extracted polysaccharide, so a long simmer or a water extract is the closest consumer analogue — see tea versus extract.
- If you have any kidney history, skip chaga. Two published nephropathy cases and an oxalate content of 14.2 g per 100 g make that an easy call.
- Buy chaga as chunks rather than powder. Simmering extracts less oxalate than swallowing the whole material — the reasoning is in our format comparison.
- Don't buy either for "immunity" as a general goal. Neither has been tested in healthy adults for that, which is the population buying it.
- If you're on immunosuppressants or have an autoimmune condition, ask first. Immune modulation is not automatically a good thing — see what immunomodulation means.
The Honest Summary
On evidence volume this isn't a contest. Trametes Versicolor has randomised survival data in The Lancet; chaga has none. On safety it isn't a contest either, and it runs the same direction: chaga has two published kidney failures and an oxalate content high enough to explain them.
The complication worth carrying is that Trametes's trials tested a pharmaceutical preparation nobody sells as a supplement. So the fair statement is that Trametes Versicolor is the better-evidenced species with an unevidenced product, while chaga is an unevidenced species with a measured hazard attached. If you're choosing one, choose Trametes — and choose it knowing what you're actually getting.
Frequently Asked Questions
Which is better, chaga or Trametes Versicolor?
Trametes Versicolor, on both evidence and safety. Its polysaccharide fraction has randomised trials with five-year survival endpoints; chaga has no completed randomised human trial and two published case reports of oxalate nephropathy.
Does Trametes Versicolor really have Lancet evidence?
Yes, but for PSK rather than for the mushroom itself. The 1994 trial randomised 262 post-gastrectomy patients and found a 73.0% five-year survival on PSK against 60.0% — using a standardised prescription-grade extract, not a dried mushroom or tea.
Is chaga bad for your kidneys?
It carries a documented risk at heavy long-term intakes. One case report measured 14.2 g of oxalate per 100 g in the powder a patient had taken for years before developing end-stage renal disease, and a second describes oxalate nephropathy presenting as nephrotic syndrome.
Can I take chaga and Trametes Versicolor together?
No interaction is documented between them, so the question is really about chaga alone. Anyone with kidney stones, reduced kidney function or high vitamin C intake should leave chaga out regardless of what it's combined with.
Which form should I buy?
Hot water is the right solvent for both, because the studied compounds in Trametes are water-soluble polysaccharides. For chaga, simmered chunks extract less oxalate than swallowing powdered material outright.
Shop Trametes Versicolor and Chaga
Dried Trametes Versicolor (100 g €29, 300 g €69, 500 g €89) simmers into the water-based preparation that matches how the studied polysaccharides are extracted, and Trametes tincture (50 ml €49) suits daily dosing. Chaga chunks (100 g €25, 300 g €39, 1 kg €59) are the lower-oxalate way to use chaga if your kidneys are healthy. Browse Immunity. Free shipping on orders over €50.
Related Articles
- Turkey Tail vs Reishi for Immune Support
- Reishi vs Chaga
- Mushrooms, Oxalates and Kidney Health
- Chaga Immune Modulation
- Trametes Versicolor: PSK/PSP Immune Guide
- Best Mushrooms for Immunity
- Chaga Side Effects and Interactions
Sources
- Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994;343(8906):1122-1126. PubMed 7910230
- Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990;31(5):261-268. PubMed 2198088
- Lee S, Lee HY, Park Y, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122. PubMed 32419395
- Kwon O, Lee S, Kim JH, et al. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore). 2022;101(10):e28854. PubMed 35451393
- Raal A, Kaldmäe H, Kütt K, et al. Chemical content and cytotoxic activity on various cancer cell lines of chaga (Inonotus obliquus) growing on Betula pendula and Betula pubescens. Pharmaceuticals (Basel). 2024;17(8):1013. PubMed 39204121